Metastatic Colorectal Cancer
Conditions
Keywords
metastatic colorectal cancer, regorafenib
Brief summary
Real-World Effectiveness of Regorafenib in the Treatment of Patients with Metastatic Colorectal Cancer- A Retrospective, Observational Study
Detailed description
To analyze the real-world usage pattern, effectiveness and factors associated with the effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer (mCRC). This retrospective, observational study included clinicopathological and follow-up data of patients with mCRC who were treated with regorafenib from June 2017 to September 2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version 4.0 was used for the analysis.
Interventions
OTHERnonintervention
Sponsors
Henan Cancer Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Inclusion Criteria: 1. Must be a pathologically proven colorectal adenocarcinoma 2. Must have been treated with regorafenib 3. Regorafenib must be used after two lines of standard antitumor therapy 2.
Exclusion criteria
1. Application is less than one course of treatment with regorafenib 2. First - or second-line treatment with regorafenib 3. Patients with multiple primary cancers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The difference in overall survival between the two groups calculated by Kaplan-Meier | 2021.7-2022.12 | Survival differences between the monotherapy and combination groups |
| The difference of OS in patients receiving different doses of regorafenib | 2021.11-2022.12 | In the real world, regorafenib was used in different dosages: 40mg,80mg,120mg,160mg,respectively. The difference in overall survival time of patients with different dosage was compared. |
| Regorafenib in combination with other drugs | 2021.7-2022.10 | In the real world, regorafenib was used in combination with chemotherapy, immunotherapy or other drugs, and the frequency of occurrence of different conditions was analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival differences among the patients with different clinical phenotypes and genotypes | 2021.7-2022.10 | To compare the survival of patients with mCRC by gender, age, tumor site and other genotypes |
Countries
China
Contacts
Primary ContactShujun Yang, bachelor
Outcome results
None listed